Peptide receptor therapies in neuroendocrine tumors

L. Bodei*, D. Ferone, C. M. Grana, M. Cremonesi, A. Signore, R. A. Dierckx, G. Paganelli

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

89 Citations (Scopus)

Abstract

Neuroendocrine tumors (NETs) are relatively rare tumors, mainly originating from the digestive system, able to produce bioactive amines and hormones. NETs tend to be slow growing and are often diagnosed when metastatic. The localization of a NETs and the assessment of the extent of disease are crucial for management. Commonly used diagnostic techniques include morphological imaging (ultrasound, computerized tomography, magnetic resonance), and functional imaging (somatostatin receptor scintigraphy, positron emission tomography techniques). Treatment is multidisciplinary and should be individualized according to the tumor type, burden, and symptoms. Therapeutic tools include surgery, interventional radiology, and medical treatments such as somatostatin analogues, interferon, chemotherapy, new targeted drugs and peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogues. NETs usually over-express somatostatin receptors, thus enabling the therapeutic use of somatostatin analogues, one of the basic tools, able to reduce signs and symptoms of hormone hypersecretion, improve quality of life, and slow tumor growth. PRRT with somatostatin analogues (90)Y-DOTATOC and (17)7Lu-DOTATATE has been explored in NETs for more than a decade. Present knowledge and clinical studies indicate that it is possible to deliver high-absorbed doses to tumors expressing sst(2) receptors, with partial and complete objective responses in up to 30% of patients. Side effects, involving the kidney and the bone marrow, are mild if adequate renal protection is used. Moreover, a consistent survival benefit is reported. As NETs may also express cholecystokinin 2, bombesin, neuropeptide Y or vasoactive intestinal peptide receptors even simultaneously, the potential availability and biological stability of radio-analogues will improve the multireceptor targeting of NETs. (J. Endocrinol. Invest. 32: 360-369, 2009) (C)2009, Editrice Kurtis

Original languageEnglish
Pages (from-to)360-369
Number of pages10
JournalJournal of endocrinological investigation
Volume32
Issue number4
Publication statusPublished - Apr-2009

Keywords

  • 177Lu-DOTATATE
  • 90Y-DOTATOC
  • neuroendocrine tumors
  • PRRT
  • RADIOLABELED SOMATOSTATIN ANALOG
  • RADIONUCLIDE THERAPY
  • GASTROENTEROPANCREATIC TUMORS
  • IN-VIVO
  • LU-177-DOTA(0),TYR(3) OCTREOTATE
  • GASTROINTESTINAL TUMORS
  • TARGETED SCINTIGRAPHY
  • ROTTERDAM EXPERIENCE
  • TYR(3) OCTREOTATE
  • LIVER METASTASES

Cite this